Analyst Available to Comment on New JUPITER Study That Shows AstraZeneca's Crestor Significantly Reduc...( WALTHAM Mass. Nov. 19 /- Graeme Green...),Health

WALTHAM, Mass., Nov. 19 /PRNewswire/ --Graeme GreenPh.D, analyst at Decision Resources, is available to discuss the results of the JUPITER study presented at the American Heart Association (AHA) Scientific Sessions this month.

The results of the 17,802-patient trial demonstrated AstraZeneca's Crestor to be effective at cutting the risk of heart attack and death among patients who seemed healthy but showed high levels of high-sensitivity C-reactive protein (hsCRP). In the study, those who had normal LDL cholesterol levels, but who were identified as being at increased cardiovascular risk due to elevated hsCRP, received either Crestor or placebo. Findings showed that those who took Crestor had a 44 percent reduction in the occurrence of a first major cardiovascular event and a 47 percent reduction in the combined risk of stroke, heart attack or cardiovascular death, compared with those who took placebo. The data also indicated that total mortality in the Crestor group was reduced by 20 percent versus the placebo group.

Dr. Green is available to discuss:

• The initial reaction from thought leaders at the AHA in response to the JUPITER study
• How the positive messaging and heightened patient awareness for Crestor after the JUPITER trial will boost sales of the brand in the near term
• The potential for changes to Crestor's label, treatment guidelines and MCO reimbursement status, and how these changes will impact Crestor's revenue
• The place of hsCRP testing in routine clinical practice
• Crestor-specific effects vs. statin class effects

To speak with Dr. Green, please contact Heather Hilty at 781-296-2536 or hhilty@dres
'/>"/>